Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| US Patent Office Issues New Transplant Patent to CareDx | ||
| By: Nasdaq / GlobeNewswire - 26 Jun 2019 | Back to overview list |
|
CareDx continues to lead innovation in transplantation BRISBANE, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the addition of a new transplant patent to the company’s intellectual property portfolio. US 10,329,607 Title: Non-invasive diagnosis of graft rejection in organ transplant patients Issued June 25, 2019 “CareDx continues to collaborate with a wide range of leading researchers in transplantation to bring innovation and advance the science in the field,” said Peter Maag, CareDx Chief Executive Officer. “This latest patent extends our position as the leading provider of genomics-based information in transplantation. Our strong leadership position allows us to focus on our commitment to improve outcomes for transplant patients.” About CareDx For more information, please visit: www.CareDx.com. CONTACTS: CareDx, Inc. Investor Relations |
||
|
||
 | Back to overview list | |